How sunitinib affects blood vessel function
Official title: Molecular mechanisms of translational control in sunitinib-induced vascular dysfunction
Funded at University of Illinois at Chicago · NIH-11050421 · Data updated 2026-11-12
This study is looking at how the cancer medication sunitinib affects the blood vessels in patients, especially how it changes the cells that line those vessels, to help understand why some people might have heart problems while taking the drug.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | January 15, 2025 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $701,890 |
| NIH project number | 1R01HL173315-01A1 |
| Project ID | NIH-11050421 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors, particularly metastatic renal cell carcinoma, who are being treated with sunitinib.
✕Less likely to help
Patients who are not receiving sunitinib or those with conditions unrelated to vascular dysfunction may not benefit from this research.
What this research studies
This research investigates how sunitinib, a medication used to treat certain cancers, impacts the function of blood vessels. It focuses on the role of endothelial cells, which line the blood vessels, and how their behavior changes in response to sunitinib treatment. By examining the molecular mechanisms involved, the study aims to uncover why some patients experience vascular dysfunction and cardiac issues while on this medication. The approach includes analyzing gene expression and protein production in endothelial cells under stress conditions induced by sunitinib.
Why it matters
Potential benefit: If successful, this research could lead to improved management of vascular side effects in patients undergoing treatment with sunitinib.
How similar studies have gone: Other research has shown that understanding the molecular mechanisms of drug-induced vascular dysfunction can lead to better therapeutic strategies, indicating potential success for this approach.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Ong, Sang Ging — University of Illinois at Chicago
- Study coordinator: Ong, Sang Ging
Related research
Other NIH-funded projects on the same topics.
-
MSC Secretome Eye Drops to Speed Healing of Corneal Wounds
A new eye drop made from stem cell–secreted factors is being tested to help adults with non-healing corneal wounds recover vision faster.
-
UIC Center for Healthy Work
A national program led by UIC aims to improve the health and well-being of workers through collaborative research and practical solutions.
-
Coordinated Oral Health Promotion for Chicago Kids
A long-running study in Chicago is following children and their caregivers to find ways to reduce tooth decay and improve daily life for families.
-
Targeting p38 MAPK to slow ALS-related axonal damage
Aims to block a specific brain-wide signaling pathway (p38 MAPK) to reduce nerve damage in people with various genetic forms of ALS.
-
Precision nanomedicine to calm inflammation and protect bone in gum disease
A new, targeted nanomedicine approach aims to reduce gum inflammation and prevent bone loss in adults with periodontal disease.
-
Role of DPP in Dental Pulp Stem Cells and their Regenerative Potential
A project explores how a natural tooth protein helps dental pulp stem cells repair and regenerate the tooth’s inner tissue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.